Alison J. Holmes

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

Medicine, Oncology, Pharmacology +17

<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Jussi Koivunen, Craig H. Mermel, Kreshnik Zejnullahu et al. · Clinical Cancer Research · 2008 · 983 citations · Full text

Medicine, Oncology, Pharmacology +17

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

David M. Jackman, Beow Y. Yeap, Lecia V. Sequist et al. · Clinical Cancer Research · 2006 · 584 citations

Medicine, Oncology, Pharmacology +15

Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer

David M. Jackman, Beow Y. Yeap, Neal I. Lindeman et al. · Journal of Clinical Oncology · 2007 · 307 citations

Medicine, Oncology, Pharmacology +17

Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib

David M. Jackman, Alison J. Holmes, Neal I. Lindeman et al. · Journal of Clinical Oncology · 2006 · 257 citations · Full text

Medicine, Infectious Diseases, Oncology +17